A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the allergen-induced early asthmatic response in subjects with mild asthma

GlaxoSmithKline Research & Development Ltd0 sites42 target enrollmentDecember 3, 2009

ConditionsAsthma MedDRA version: 12.1Level: LLTClassification code 10001705Term: Allergic asthma

DrugsALK-lyophilisiert SQ - 6 Gräsermischung ALK-lyophilisiert SQ - Katzenhaare ALK-lyophilisiert SQ - Milbe Dermatophagoides pteronyssinus

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Asthma
Sponsor: GlaxoSmithKline Research & Development Ltd
Enrollment: 42
Status: Active, not recruiting
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 3, 2009

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

GlaxoSmithKline Research & Development Ltd

Eligibility Criteria

Inclusion Criteria

•A subject will be eligible for inclusion in this study only if all of the following criteria apply:
•1\.Males and females aged 18 to 65 years inclusive.
•2\.AST, ALT, alkaline phosphatase and bilirubin ? 1\.5xULN (isolated bilirubin
•\>1\.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
•3\.Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
•4\.Body mass index within the range 18\.5\-35\.0 kilograms/metre2 (kg/m2\).
•5\.A female subject is eligible to participate if she is of:
•Non\-childbearing potential defined as pre\-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \< 40 pg/ml (\<140 pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section ?8\.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post\-menopausal status prior to study enrollment. For most forms of HRT, at least 2\-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post\-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
•Child\-bearing potential and agrees to use one of the contraception methods listed in Section 8\.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 5 terminal half\-live post\-last dose.
•6\.Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short\-acting beta \-agonist therapy by inhalation.

Exclusion Criteria

•A subject will not be eligible for inclusion in this study if any of the following criteria apply:
•1\.Past or present disease, which as judged by the investigator or medical monitor, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, bronchiectasis or pulmonary fibrosis).
•2\.Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
•3\.Clinically significant abnormalities in safety laboratory analysis at screening.
•4\.Subject is hypertensive at screening. Hypertension at screening is defined as persistent systolic BP \>150 mmHg or diastolic BP \> 90mmHg. Subject with controlled hypertension may be included.
•5\.Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.
•6\.History of life\-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic seizures.
•7\.Symptomatic with hay fever at screening or predicted to have symptomatic hayfever during days 21\-29 of a treatment period of the study.
•8\.Administration of oral or injectable steroids within 5 weeks of screening or intranasal and/or inhaled steroids within 4 weeks of the screening visit.
•9\.Unable to abstain from other medications including non\-steroidal anti\-inflammatory drugs (NSAIDs), anti\-depressant drugs, anti\-asthma anti\-rhinitis or hay fever medication, other than antihypertensive medication and paracetamol (up to 4 g per day) for the treatment of minor ailments e.g. headache from 14 days before screening until the follow\-up visit.